Belatacept after kidney transplantation in adolescents: a retrospective study.
Regardless of recipient age at kidney transplantation (KTx), patients are at greatest risk for graft loss in adolescence, partly due to nonadherence to an oral immunosuppressive regimen. Belatacept, a non-nephrotoxic, first-in-class immunosuppressant that inhibits costimulation of T cells requires intravenous application only every 4 weeks, potentially leading to better adherence. However, it is only approved for use in adults. We report here the findings of the first study of belatacept in adolescents, comprising all patients in our department switched to belatacept post-KTx. Six patients (median age 15.5 years) were switched after a median of 7.5 months (range 23 days to 12 years), treatment range 3-28 months (cumulative 83 months): Three patients switched early (<3 months after KTx) had increased estimated glomerular filtration rate (GFR); one patient switched 12 years post-KTx has stable GFR; two patients were switched following rapid decline of and with markedly impaired GFR, changing slope in one patient. One patient had one acute rejection. In addition of two patients who received belatacept for other conditions, the only relevant adverse event was neutropenia (after a cumulative 109 months). Belatacept as primary immunosuppression is an option in Epstein-Barr virus-seropositive nonadherent adolescents if administered sufficiently early before deterioration of graft function.
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Christian
C
Lerch
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Nele K
NK
Kanzelmeyer
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Thurid
T
Ahlenstiel-Grunow
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Kerstin
K
Froede
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Martin
M
Kreuzer
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Jens
J
Drube
Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany.
Murielle
M
Verboom
Department of Pediatric Nephrology, Hannover Medical School, Hannover, Germany.
Lars
http://orcid.org/0000-0002-3635-6418
L
Pape
D000069594:Abatacept / Q000008:administration & dosage*; D000293:Adolescent; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D008297:Male; D055118:Medication Adherence; D012189:Retrospective Studies; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D000069594:Abatacept
adolescence; belatacept; immunosuppression; nonadherence; pediatric kidney transplantation